Loading clinical trials...
Loading clinical trials...
Prevalence and Risk Factors Associated With Resistance to Antiviral Therapy in Egyptian Patients With Chronic Hepatitis B Virus Infection
This study aims to determine the prevalence of antiviral drug resistance among Egyptian patients with chronic hepatitis B virus (HBV) infection and to identify the associated demographic, clinical, and virological risk factors. Understanding patterns of resistance will help improve treatment selection and optimize long-term management strategies for HBV patients.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Start Date
December 1, 2025
Primary Completion Date
June 1, 2026
Completion Date
December 1, 2026
Last Updated
December 10, 2025
2,000
ESTIMATED participants
Lead Sponsor
Amira Mohamed Zidan
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions